Clinical and technological validation of locally-installed, privacy-compliant, and hematology-tailored ambient AI platform for clinical report transcription assistance and clinical trial patient management
Mattia Delleani(IRCCS Humanitas Research Hospital), Matteo Della Porta(University of Milan), Saverio D’Amico(Istituti di Ricovero e Cura a Carattere Scientifico), Marilena Bicchieri(Istituti di Ricovero e Cura a Carattere Scientifico), Victor Savevski(Humanitas University), Alessia Campagna(Humanitas University), Elisabetta Sauta(IRCCS Humanitas Research Hospital), Matteo Zampini(IRCCS Humanitas Research Hospital), Matteo Brindisi(University of Calabria), Cristina Astrid Tentori(Humanitas University), Ivan Ferrari(IRCCS Humanitas Research Hospital), Gabriele Todisco(Humanitas University), Marta Ubezio(Humanitas University), Laura Crisafulli(Humanitas University), Giulia Maggioni(Humanitas University), Patrizia Meroni(IRCCS Humanitas Research Hospital), Luca Lanino(Humanitas University), Gianluca Asti(IRCCS Humanitas Research Hospital), Alessandro Buizza(IRCCS Humanitas Research Hospital), Elena Zazzetti(IRCCS Humanitas Research Hospital), Antonio Russo(University of Palermo), Armando Santoro(IRCCS Humanitas Research Hospital), Nicole Pinocchio(IRCCS Humanitas Research Hospital), Alessandro Bruseghini(IRCCS Humanitas Research Hospital), Elena Riva(Humanitas University), Eleonora Iascone(IRCCS Humanitas Research Hospital), Francesca Ficara(Humanitas University)
Cited by 0
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532